A multi-centre, randomized, double blind, parallel group study to investigate efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

Trial Profile

A multi-centre, randomized, double blind, parallel group study to investigate efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs ONO 5334 (Primary) ; Alendronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms OCEAN
  • Most Recent Events

    • 05 Dec 2012 Planned number of patients changed from 265 to 285 as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Quantitative computed tomography results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 20 Sep 2011 Results assessing changes in levels of bone turnover markers presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top